K. Phillips

Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests.
20233 citationsauthor #2
Ten health policy challenges for the next 10 years
20239 citationsauthor #1
Introducing the inaugural issue of Health Affairs Scholar: Emerging and Global Health Policy (HAS)
20232 citationsauthor #1
Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy
202312 citationsauthor #8
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
202310 citationsauthor #7
Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access.
202221 citationsauthor #3
CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement.
20229 citationsauthor #1
Geriatricians’ Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer’s Disease: A Qualitative Study
20225 citationsauthor #5
Genetic counselors' experience with reimbursement and patient out‐of‐pocket cost for multi‐cancer gene panel testing for hereditary cancer syndromes
20222 citationsauthor #10
Assessments of the Value of New Interventions Should Include Health Equity Impact
20224 citationsauthor #3
Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants
20215 citationsauthor #4
Private Payer Coverage Policies for ApoE-e4 Genetic Testing
20219 citationsauthor #4
Multicancer hereditary syndrome testing: Genetic counselors’ perspectives.
20210 citationsauthor #3
Laboratory business models and practices: implications for availability and access to germline genetic testing
20215 citationsauthor #5
Financing of germline testing: implications for availability and access
20210 citationsauthor #9
Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases.
20215 citationsauthor #2
Worldwide exome and genome sequencing: who has access, who pays, and what are solutions for implementation challenges?
20210 citationsauthor #1
Availability and funding of clinical genomic sequencing globally
202170 citationsauthor #1
Influence of payer coverage and out‐of‐pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings
202125 citationsauthor #7
US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER).
202118 citationsauthor #1
Complicated legacies: The human genome at 20
202116 citationsauthor #7
Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants
20210 citationsauthor #4
The Coming Era Of Precision Health
20212 citationsauthor #1
Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy.
20203 citationsauthor #1
Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing.
202010 citationsauthor #3
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
202031 citationsauthor #3
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.
202045 citationsauthor #6
Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
202018 citationsauthor #3
Introduction to Themed Papers: Methods for Moving Evaluation of Precision Medicine into Practice and Policy
20200 citationsauthor #1
Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation.
202029 citationsauthor #1
Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
202012 citationsauthor #7
PCV3 Global Landscape of Clinical Genomic Sequencing: Who, Where, and How?
20200 citationsauthor #1
Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs.
201922 citationsauthor #1
Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS)
201947 citationsauthor #6
Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?
20190 citationsauthor #1
Insurance coverage for genomic tests
201822 citationsauthor #1
Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions.
201861 citationsauthor #1
Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?
2018200 citationsauthor #1
A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service
20189 citationsauthor #6
Precision Medicine: From Science To Value.
2018571 citationsauthor #2
Private Payer Coverage Policies for Whole Exome Sequencing (WES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited
201833 citationsauthor #5
The Cost Of Integrating Whole Genome Sequencing Into The Care Of Cardiomyopathy Patients: Sensitivity And Scenario Analyses
20180 citationsauthor #2
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.
201823 citationsauthor #10
Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?
201824 citationsauthor #1
New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare.
20186 citationsauthor #1
Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project.
201817 citationsauthor #2
The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.
201812 citationsauthor #1
Measuring the Economic Value of Sequencing: Why is it Important, Why is it Challenging, and What are Solutions
20180 citationsauthor #1
Preventive Services: The Authors Respond
20180 citationsauthor #1
Short Term Costs of Integrating Whole Genome Sequencing into Primary Care and Cardiology Settings: A Pilot Randomized Trial
201827 citationsauthor #3
PMU116 - PATIENT-REPORTED OUTCOMES IN A PILOT RANDOMIZED TRIAL OF GENOME SEQUENCING
20180 citationsauthor #2
Payer coverage policies for multigene tests
201748 citationsauthor #1
Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
201722 citationsauthor #6
Management of menopause-related symptoms - In response
20170 citationsauthor #4
Underuse of b-Blockers Following Myocardial Infarction
20170 citationsauthor #1
Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction.
20175 citationsauthor #1
Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive?
20171 citationsauthor #7
Payer Decision-Making for Next Generation Sequencing-Based Genetic Tests: Insights from cell-free DNA prenatal genetic screening
20170 citationsauthor #6
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research
201756 citationsauthor #1
EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS
201718 citationsauthor #6
"What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.
201716 citationsauthor #1
The price of whole-genome sequencing may be decreasing, but who will be sequenced?
201710 citationsauthor #11
Breast cancer testing strategies and the utilization of targeted therapies: Data from the real world.
20164 citationsauthor #2
Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care.
201613 citationsauthor #1
Consistency in SeW-Reports of HIV Testing: Longitudinal Findings from the National
20160 citationsauthor #1
Payer decision making for next-generation sequencing–based genetic tests: insights from cell-free DNA prenatal screening
201624 citationsauthor #6
Personalized medicine:: economic evalution and evidence
20161 citationsauthor #1
Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review
201529 citationsauthor #5
Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT).
20150 citationsauthor #6
Availability and payer coverage of BRCA1/2 tests and gene panels
201522 citationsauthor #5
Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.
201518 citationsauthor #5
Key emerging themes for assessing the cost-effectiveness of reporting incidental findings
20155 citationsauthor #1
Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample
201514 citationsauthor #5
Potential public sector cost-savings from over-the-counter access to oral contraceptives.
201530 citationsauthor #3
Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing
201517 citationsauthor #1
Barriers to insurance coverage of next-generation tumor sequencing by U.S. payers.
20141 citationsauthor #4
Using the Coronary Artery Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis
2014112 citationsauthor #5
Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting
20140 citationsauthor #6
Private Companies Providing Health Care Price Data: Who Are They and What Information do They Provide?
201411 citationsauthor #1
Cost-Utility Analysis of Practice Deviations From Guidelines in HER2-Targeted Testing and Treatment for Breast Cancer
20140 citationsauthor #6
Genomic sequencing: assessing the health care system, policy, and big-data implications.
201469 citationsauthor #1
Economic Perspectives on Personalized Health Care and Prevention
201315 citationsauthor #1
The economic value of personalized medicine tests: what we know and what we need to know
2013103 citationsauthor #1
The EGAPP initiative: lessons learned
201343 citationsauthor #18
Utilization of cardiac monitoring tests in women with nonmetastatic breast cancer treated with trastuzumab.
20130 citationsauthor #4
Abstract 11670: Using the Coronary Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis
20121 citationsauthor #4
User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives.
201225 citationsauthor #3
Differences in US healthcare coverage policies in BRCA testing and potential implications.
20123 citationsauthor #3
Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome.
201231 citationsauthor #4
Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome.
20122 citationsauthor #4
Using the Coronary Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis
20121 citationsauthor #4
Genomic testing and therapies for breast cancer in clinical practice.
201119 citationsauthor #2
How does cost matter in health-care discrete-choice experiments?
201167 citationsauthor #7
Tradeoffs of Using Administrative Claims and Medical Records to Identify the Use of Personalized Medicine for Patients With Breast Cancer
201130 citationsauthor #2
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling
201143 citationsauthor #4
Health technology assessment and private payers's coverage of personalized medicine.
201111 citationsauthor #3
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
201141 citationsauthor #3
Health technology assessment and private payers' coverage of personalized medicine.
201149 citationsauthor #3
Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer
2011212 citationsauthor #9
Economic evaluation of targeted cancer interventions: Critical review and recommendations
201123 citationsauthor #7

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT